AdaptHealth posts Q3 loss due to goodwill impairment charge
Overview
US home medical equipment provider's Q3 revenue rose 10.9% yr/yr, slightly missing analyst expectations
Company posted a large net loss due to $184.8 mln goodwill impairment
Adjusted EBITDA for Q3 fell 2.9% yr/yr
Outlook
AdaptHealth raises 2026 net revenue guidance to $2.88 bln-$2.90 bln from $2.85 bln-$2.89 bln
Company lifts 2026 adj EBITDA outlook to $510 mln-$525 mln from $490 mln-$520 mln
AdaptHealth lowers 2026 free cash flow forecast to $50 mln-$75 mln from $80 mln-$120 mln
Result Drivers
CAPITATED AGREEMENT - Co said exclusive capitated agreement with national integrated delivery network improved contract profitability through lower labor costs
SEGMENT GROWTH - Co reported organic revenue growth across Sleep Health, Respiratory Health and Wellness at Home segments
PORTFOLIO FOCUS - Co said pending sale of Diabetes Health business will allow greater focus on core segments
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Miss* | $745.65 mln | $746.45 mln (8 Analysts) |
Q3 Loss Per Share | $1.13 | ||
Q3 Net Loss | $152.77 mln | ||
Q3 Operating Income | Miss | -$155.92 mln | $38.47 mln (3 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AdaptHealth Corp. is $9.00, about 52.3% above its November 2 closing price of $5.91
The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 10 three months ago
Reuters Recommended Reads
Nov 3 - Fresenius Medical cuts 2026 profit outlook as US treatment decline deepens
Nov 3 - Henry Schein Q3 sales slightly miss, raises 2026 profit outlook
Nov 2 - Hinge Health Q3 revenue jumps 52%, beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)